SE0000772D0 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
SE0000772D0
SE0000772D0 SE0000772A SE0000772A SE0000772D0 SE 0000772 D0 SE0000772 D0 SE 0000772D0 SE 0000772 A SE0000772 A SE 0000772A SE 0000772 A SE0000772 A SE 0000772A SE 0000772 D0 SE0000772 D0 SE 0000772D0
Authority
SE
Sweden
Prior art keywords
sup
chemical compounds
solvates
sub
formula
Prior art date
Application number
SE0000772A
Other languages
Swedish (sv)
Inventor
David Blomberg
Mikael Dahlstroem
Ingemar Starke
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0000772A priority Critical patent/SE0000772D0/en
Publication of SE0000772D0 publication Critical patent/SE0000772D0/en
Priority to CA002401055A priority patent/CA2401055A1/en
Priority to DE60107395T priority patent/DE60107395T2/en
Priority to US10/220,877 priority patent/US6906058B2/en
Priority to EP01909970A priority patent/EP1263747B1/en
Priority to JP2001565349A priority patent/JP5204361B2/en
Priority to KR1020027011768A priority patent/KR20020079990A/en
Priority to AT01909970T priority patent/ATE283266T1/en
Priority to PCT/GB2001/000909 priority patent/WO2001066533A1/en
Priority to AU2001237556A priority patent/AU2001237556B2/en
Priority to NZ520951A priority patent/NZ520951A/en
Priority to AU3755601A priority patent/AU3755601A/en
Priority to BR0109011-9A priority patent/BR0109011A/en
Priority to MXPA02008600A priority patent/MXPA02008600A/en
Priority to IL15129601A priority patent/IL151296A0/en
Priority to CN01806160A priority patent/CN1416425A/en
Priority to ZA200206739A priority patent/ZA200206739B/en
Priority to NO20024217A priority patent/NO20024217L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms

Abstract

The present invention relates to compounds of formula (I) wherein R<SUP>1 </SUP>and R<SUP>2 </SUP>are independently selected from C<SUB>1-6</SUB>alkyl; one of R<SUP>4 </SUP>and R<SUP>5 </SUP>is a group of formula (IA): R<SUP>3</SUP>, R<SUP>6</SUP>, R<SUP>7</SUP>, R<SUP>8</SUP>, R<SUP>9</SUP>, R<SUP>10 </SUP>and R<SUP>11 </SUP>and the other of R<SUP>4 </SUP>and R<SUP>5 </SUP>are as defined within, pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and there use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described.
SE0000772A 2000-03-08 2000-03-08 Chemical compounds SE0000772D0 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
SE0000772A SE0000772D0 (en) 2000-03-08 2000-03-08 Chemical compounds
CN01806160A CN1416425A (en) 2000-03-08 2001-03-05 1,5-bemzothiazepines and their use as hypolipidaemics
PCT/GB2001/000909 WO2001066533A1 (en) 2000-03-08 2001-03-05 1,5-benzothiazepines and their use as hypolipidaemics
NZ520951A NZ520951A (en) 2000-03-08 2001-03-05 1,5-benzothiazepines and their use as hypolipidaemics
US10/220,877 US6906058B2 (en) 2000-03-08 2001-03-05 1,5-Benzothiazepines and their use as hypolipidaemics
EP01909970A EP1263747B1 (en) 2000-03-08 2001-03-05 1,5-benzothiazepines and their use as hypolipidaemics
JP2001565349A JP5204361B2 (en) 2000-03-08 2001-03-05 1,5-Benzothiazepine and its use as a lipid-lowering drug
KR1020027011768A KR20020079990A (en) 2000-03-08 2001-03-05 1,5-benzothiazepines and their use as hypolipidaemics
AT01909970T ATE283266T1 (en) 2000-03-08 2001-03-05 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDEMICS
CA002401055A CA2401055A1 (en) 2000-03-08 2001-03-05 1,5-benzothiazepines and their use as hypolipidaemics
AU2001237556A AU2001237556B2 (en) 2000-03-08 2001-03-05 1,5-benzothiazepines and their use as hypolipidaemics
DE60107395T DE60107395T2 (en) 2000-03-08 2001-03-05 1,5-BENZOTHIAZEPINE AND ITS USE AS HYPOLIPIDÄMIKA
AU3755601A AU3755601A (en) 2000-03-08 2001-03-05 1,5-benzothiazepines and their use as hypolipidaemics
BR0109011-9A BR0109011A (en) 2000-03-08 2001-03-05 Compound, process for preparation and use thereof, method for producing an ibat inhibiting effect on a warm-blooded animal, and pharmaceutical composition
MXPA02008600A MXPA02008600A (en) 2000-03-08 2001-03-05 1,5 benzothiazepines and their use as hypolipidaemics.
IL15129601A IL151296A0 (en) 2000-03-08 2001-03-05 1,5-benzothiazepines and their use as hypolipidaemics
ZA200206739A ZA200206739B (en) 2000-03-08 2002-08-22 1,5-benzothiazepines and their use as hypolipidaemics.
NO20024217A NO20024217L (en) 2000-03-08 2002-09-04 1,5-benzothiazepines and their use as hypolid agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0000772A SE0000772D0 (en) 2000-03-08 2000-03-08 Chemical compounds

Publications (1)

Publication Number Publication Date
SE0000772D0 true SE0000772D0 (en) 2000-03-08

Family

ID=20278738

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0000772A SE0000772D0 (en) 2000-03-08 2000-03-08 Chemical compounds

Country Status (17)

Country Link
US (1) US6906058B2 (en)
EP (1) EP1263747B1 (en)
JP (1) JP5204361B2 (en)
KR (1) KR20020079990A (en)
CN (1) CN1416425A (en)
AT (1) ATE283266T1 (en)
AU (2) AU2001237556B2 (en)
BR (1) BR0109011A (en)
CA (1) CA2401055A1 (en)
DE (1) DE60107395T2 (en)
IL (1) IL151296A0 (en)
MX (1) MXPA02008600A (en)
NO (1) NO20024217L (en)
NZ (1) NZ520951A (en)
SE (1) SE0000772D0 (en)
WO (1) WO2001066533A1 (en)
ZA (1) ZA200206739B (en)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG26979A (en) * 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0121337D0 (en) * 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) * 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
IL160691A0 (en) * 2001-09-08 2004-08-31 Astrazeneca Ab Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment of hyperlipidaemia
SE0104333D0 (en) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0201850D0 (en) * 2002-01-26 2002-03-13 Astrazeneca Ab Therapeutic treatment
AU2003203482B2 (en) 2002-04-09 2005-06-02 Syngenta Participations Ag Process for the preparation of cyclic diketones
GB0209467D0 (en) * 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) * 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
BR0311932A (en) * 2002-06-20 2005-03-22 Astrazeneca Ab Compound, pharmaceutical formulation, method for treating or preventing insulin resistance, use of a compound, process for preparing a compound, and combined treatment
GB0304194D0 (en) * 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
GB0314131D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
EP1836161B1 (en) 2004-12-22 2016-07-20 BHI Limited Partnership Methods and compositions for treating amyloid-related diseases
AR057828A1 (en) * 2005-09-29 2007-12-19 Astrazeneca Ab COMPOUNDS DERIVED FROM AZETIDINE, ITS PREPARATION AND PHARMACEUTICAL COMPOSITION
PT3851447T (en) 2006-10-12 2023-12-11 Bellus Health Inc Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
ES2445049T3 (en) 2007-03-08 2014-02-27 Albireo Ab Derivatives of 3-phenylpropionic acid and its use in the treatment of inflammatory bowel disease
EP2367554A4 (en) * 2008-11-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
ES2552657T3 (en) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibitors of the recycling of bile acids and satiogens for the treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
PT2637646T (en) 2010-11-08 2016-08-17 Albireo Ab A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
SG190029A1 (en) 2010-11-08 2013-06-28 Albireo Ab Ibat inhibitors for the treatment of liver diseases
CN104023718B (en) 2011-10-28 2017-04-05 鲁美纳医药公司 For treating the bile acid recycling inhibitors of high cholemia and cholestatic liver disease
BR112014010223B8 (en) 2011-10-28 2021-02-23 Lumena Pharmaceuticals Llc use of a composition comprising bile acid recycling inhibitors and pediatric dosage form
KR20230152818A (en) 2013-03-15 2023-11-03 샤이어 휴먼 지네틱 테라피즈 인크. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
RU2015139732A (en) 2013-03-15 2017-04-24 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Bile Acid Recirculation Inhibitors for the Treatment of Barrett's Esophagus and Gastroesophageal Reflux Disease
JO3301B1 (en) 2013-04-26 2018-09-16 Albireo Ab Crystal modifications of elobixibat
KR102560954B1 (en) 2014-06-25 2023-07-31 이에이 파마 가부시키가이샤 Solid preparation, and method for preventing or reducing discoloration thereof
KR101674806B1 (en) * 2014-10-20 2016-11-10 씨제이헬스케어 주식회사 Novel aminoalkylbenzothiazepine derivatives and use thereof
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
JP6954926B2 (en) 2016-02-09 2021-10-27 アルビレオ・アクチボラグ Oral cholestyramine preparation and its use
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
EP3413878B1 (en) 2016-02-09 2021-04-14 Albireo AB Oral cholestyramine formulation and use thereof
KR101844184B1 (en) * 2017-07-21 2018-04-02 씨제이헬스케어 주식회사 Use of an aminoalkylbenzothiazepine derivative
CN111032019B (en) 2017-08-09 2022-07-05 阿尔比里奥公司 Cholestyramine granules, oral cholestyramine preparation and application thereof
CN110996915B (en) 2017-08-09 2023-10-03 阿尔比里奥公司 Cholestyramine pellet, oral cholestyramine preparation and application thereof
US10428109B1 (en) 2018-03-09 2019-10-01 Elobix Ab Process for the preparation of 1,5-benzothiazepine compounds
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP3802504B1 (en) 2018-06-05 2023-01-18 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
CA3100691A1 (en) 2018-06-20 2019-12-26 Albireo Ab Crystal modifications of odevixibat
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
JP2022519664A (en) * 2019-02-06 2022-03-24 アルビレオ・アクチボラグ Benzodiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
RS63899B1 (en) 2019-02-06 2023-02-28 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
AU2020221239A1 (en) 2019-02-12 2021-09-16 Mirum Pharmaceuticals, Inc. Methods for treating cholestasis
AR120674A1 (en) 2019-12-04 2022-03-09 Albireo Ab BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID
CN114761080A (en) * 2019-12-04 2022-07-15 阿尔比里奥公司 Benzothia (di) azepin compounds and their use as bile acid modulators
JP2023504645A (en) * 2019-12-04 2023-02-06 アルビレオ・アクチボラグ Benzothia(di)azepine compounds and their use as bile acid modulators
EP4069247A1 (en) 2019-12-04 2022-10-12 Albireo AB Benzothiadiazepine compounds and their use as bile acid modulators
PT4069360T (en) 2019-12-04 2024-03-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP2023504647A (en) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ Benzothia(di)azepine compounds and their use as bile acid modulators
WO2021110885A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
TW202134220A (en) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 Benzothia(di)azepine compounds and their use as bile acid modulators
AR120683A1 (en) 2019-12-04 2022-03-09 Albireo Ab BENZOTHI(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILIARY ACID
JP2023537285A (en) 2020-08-03 2023-08-31 アルビレオ・アクチボラグ Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022101379A1 (en) 2020-11-12 2022-05-19 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
AU2021390172A1 (en) 2020-12-04 2023-06-22 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2023237728A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
US20240067617A1 (en) * 2022-07-05 2024-02-29 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9203347D0 (en) 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
ZA941003B (en) 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
ZA956647B (en) 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
US5994391A (en) 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
JP3304093B2 (en) 1994-09-13 2002-07-22 モンサント カンパニー Novel benzothiepines with inhibitory activity on ileal bile acid transport and taurocholate absorption
GB9423172D0 (en) * 1994-11-17 1995-01-04 Wellcom Foundation The Limited Hypolipidemic benzothiazepines
CN1110494C (en) 1996-03-11 2003-06-04 G·D·瑟尔公司 Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
GB9704208D0 (en) 1997-02-28 1997-04-16 Glaxo Group Ltd Chemical compounds
WO1998040375A2 (en) 1997-03-11 1998-09-17 G.D. Searle & Co. COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS
DK0864582T3 (en) 1997-03-14 2003-09-29 Aventis Pharma Gmbh Hypolidemic 1,4-benzothiazepine-1,1-dioxides
GB2338810B (en) 1997-12-31 2001-09-12 Infodream Corp Bubble edit
GB9800428D0 (en) 1998-01-10 1998-03-04 Glaxo Group Ltd Chemical compounds
DE19825804C2 (en) 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxide derivatives, processes for their preparation and medicaments containing these compounds
BR9916564A (en) 1998-12-23 2002-01-29 Searle Llc Combinations for cardiovascular indications
HUP0201972A3 (en) 1998-12-23 2005-06-28 G D Searle Llc Chicago Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
BR9916565A (en) 1998-12-23 2002-01-29 Searle Llc Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
HUP0104593A3 (en) 1998-12-23 2004-10-28 G D Searle Llc Chicago Combinations of benzothiepine ileal bile acid transport inhibitor and nicotinic acid derivatives for cardiovascular indications
ES2189529T3 (en) 1998-12-23 2003-07-01 Searle Llc INHIBITOR COMBINATIONS FOR THE TRANSPORT OF BILIAR ACIDS IN THE ILEON AND COMPLEXING AGENTS FOR CARDIOVASCULAR INDICATIONS.
CA2362147A1 (en) 1999-02-12 2000-08-17 Steve A. Kolodziej 1,2-benzothiazepines for the treatment of hyperlipidemic diseases
DE19916108C1 (en) 1999-04-09 2001-01-11 Aventis Pharma Gmbh 1,4-Benzothiazepine-1,1-dioxide derivatives substituted with sugar residues, process for their preparation and their use
SE9901387D0 (en) 1999-04-19 1999-04-19 Astra Ab New pharmaceutical foromaulations
CA2400021A1 (en) 2000-02-18 2001-08-23 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
AU2001247331A1 (en) 2000-03-10 2001-09-24 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
AU2001240115A1 (en) 2000-03-10 2001-09-24 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
US20020183307A1 (en) 2000-07-26 2002-12-05 Tremont Samuel J. Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
SE0003766D0 (en) 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
IL160691A0 (en) 2001-09-08 2004-08-31 Astrazeneca Ab Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment of hyperlipidaemia

Also Published As

Publication number Publication date
JP5204361B2 (en) 2013-06-05
CA2401055A1 (en) 2001-09-13
AU3755601A (en) 2001-09-17
EP1263747A1 (en) 2002-12-11
AU2001237556B2 (en) 2004-10-07
MXPA02008600A (en) 2003-02-24
NO20024217D0 (en) 2002-09-04
EP1263747B1 (en) 2004-11-24
ATE283266T1 (en) 2004-12-15
DE60107395T2 (en) 2005-12-01
JP2003525933A (en) 2003-09-02
BR0109011A (en) 2003-06-03
IL151296A0 (en) 2003-04-10
KR20020079990A (en) 2002-10-21
ZA200206739B (en) 2003-11-24
US20030166927A1 (en) 2003-09-04
CN1416425A (en) 2003-05-07
US6906058B2 (en) 2005-06-14
NZ520951A (en) 2004-05-28
NO20024217L (en) 2002-10-09
WO2001066533A1 (en) 2001-09-13
DE60107395D1 (en) 2004-12-30

Similar Documents

Publication Publication Date Title
SE0000772D0 (en) Chemical compounds
IS7170A (en) Benzothiazepines and benzothiadiazepine derivatives with anti-ileal bile acid transport (IBAT) for the treatment of liposuction
NO20032829D0 (en) Chemical connections
UY27431A1 (en) CHEMICAL COMPOUNDS
UY27435A1 (en) CHEMICAL COMPOUNDS
GB0121621D0 (en) Chemical compounds
MY134270A (en) Peptides derivatives comprising thiazepine group for the treatment of hyperlipidemic conditions
WO2003091232A3 (en) Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them
EP0845985A4 (en) Non-steroidal sulfatase inhibitor compounds and their method of use
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
EA200101109A1 (en) DERIVATIVES 1-TRIFTOROMETHYL-4-HYDROXY-7-PIPERIDINYL-AMINOMETHILKHROMAN
HK1075656A1 (en) New piperidinyl-alkylamino-pyridazinone derivatives, a process for the preparation thereof and pharmaceutical compositions containing said compounds
YU79401A (en) 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives